Printer Friendly

NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT

 SEATTLE, Jan. 7 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced the appointment of John M. Reno, Ph.D., as vice president, research & development. Dr. Reno has served as director of product development, director of product development and manufacturing, and director of research & development.
 Dr. Reno joined NeoRx in 1984 as a senior scientist and became one of the company's leading contributors. In particular, he patented the method of linking technetium-99m directly to antibodies, a technology now in use by several companies, and another method of link technetium-99m to plasminogen activator (t-PA) to image blood clots.
 Dr. Reno received his Ph.D. in Biochemistry from Michigan State University, focusing on novel inhibitors of herpes viruses that have become the basis of current approaches to treatment of these diseases. He then held progressively more senior positions at Dow Chemical, where he was responsible for overcoming the technical hurdles in developing the first sensitive, instrument-based latex immunoassay.
 "Under Dr. Reno's leadership, NeoRx scientists have overcome the barriers of antibody delivery to tumor versus normal organs. This promises to be a major breakthrough in antibody-targeted cancer therapy," said Paul Abrams, M.D., J.D., NeoRx's president and CEO. "Dr. Reno's track record, both in generating and then transforming discoveries into practical formulations, make him the ideal person to lead our research and development efforts. We are very pleased that he has accepted this new level of responsibility at the company."
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA for two OncoTrac(R) cancer imaging products and has completed a phase III trial for a third. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 1/7/93
 /CONTACT: Robert M. Littauer, vice president and chief financial officer of NeoRx, 206-286-2519; or Anthony J. Russo, Ph.D., or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU: PER

TS-SH -- NY050 -- 2649 01/07/93 11:58 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1993
Words:354
Previous Article:NORTHSTAR COMPUTER FORMS REPORTS RECORD FOURTH QUARTER AND YEAR END SALES
Next Article:NEORX APPOINTS ROBERT SCHROFF AS VICE PRESIDENT & GENERAL MANGER, CARDIOVASCULAR PRODUCTS
Topics:


Related Articles
NEORX ACQUIRES PRE-TARGETING TECHNOLOGY FROM STANFORD UNIVERSITY
NEORX ANNOUNCES ENHANCED TUMOR DOSE FROM PRE-TARGETING IN PRECLINICAL MODELS
NEORX APPOINTS ROBERT SCHROFF AS VICE PRESIDENT & GENERAL MANGER, CARDIOVASCULAR PRODUCTS
NEORX REPORTS FIRST QUARTER 1993 RESULTS
NEORX PROMOTES ROBERT LITTAUER TO SENIOR VICE PRESIDENT
NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT
NEORX REPORTS SECOND QUARTER 1993 RESULTS
NEORX DEFEATS IMMUNOMEDICS' ATTEMPT TO DISMISS PATENT INFRINGEMENT SUIT
NEORX REPORTS 1994 FIRST QUARTER RESULTS
OXFORD MOLECULAR GROUP SIGNS SECOND PROTEIN DESIGN COLLABORATION WITH NEORX CORP.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters